INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Contingent Liabilities History
[Standalone]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹0.98 Cr | ₹0.95 Cr | ₹0.67 Cr | ₹0.59 Cr | - |
What is the latest Contingent Liabilities ratio of INDO US BIOTECH ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹0.98 Cr |
Mar2023 | ₹0.95 Cr |
Mar2022 | ₹0.67 Cr |
Mar2021 | ₹0.59 Cr |
Mar2020 | - |
How is Contingent Liabilities of INDO US BIOTECH Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹0.98 Cr | 2.84 | |
Mar2023 | ₹0.95 Cr | 42.64 | |
Mar2022 | ₹0.67 Cr | 13.27 | |
Mar2021 | ₹0.59 Cr | 0 | |
Mar2020 | - | - |
Compare Contingent Liabilities of peers of INDO US BIOTECH
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
INDO US BIOTECH | ₹308.6 Cr | -3.6% | 3.7% | -19.6% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹12,934.7 Cr | -4.3% | -4.8% | 17.2% | Stock Analytics | |
KAVERI SEED COMPANY | ₹6,436.8 Cr | -4.4% | -9.7% | 36.7% | Stock Analytics | |
VENKYS (INDIA) | ₹2,264.3 Cr | -1.7% | -0.5% | -13.9% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,435.5 Cr | -4.3% | -6.5% | -30.7% | Stock Analytics | |
MANGALAM GLOBAL ENTERPRISE | ₹481.8 Cr | -3.4% | 12.2% | NA | Stock Analytics |
INDO US BIOTECH Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INDO US BIOTECH | -3.6% |
3.7% |
-19.6% |
SENSEX | 1.6% |
1% |
7% |
You may also like the below Video Courses